Abstract
Chagas disease is a public health problem, particularly in Latin America. The available treatment consists of two poorly effective drugs in the chronic phase of this parasitic disease. Considering the lack of effective treatment, alternatives are sought, such as the search focused on the biological targets of the etiologic agent. Based on this strategy, the role of Trypanosoma cruzi sterol 14α-demethylase (TcCYP51) in ergosterol seems promising. In this work, we apply the virtual screening approach to a proposal to repurpose U.S. Food and Drug Administration (FDA)-approved drugs. We combined computational techniques and used rigorous validation to identify putative inhibitors from the FDA-approved drug library. The results indicated one of these drugs as a putative inhibitor of the TcCYP51 enzyme.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
